Study of XL820 in Adults With Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- Registration Number
- NCT00129571
- Lead Sponsor
- Exelixis
- Brief Summary
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Advanced solid tumor
- Cancer for which standard therapies do not exist or are no longer effective
- Life expectancy of > 3 months
- Adequate bone marrow, liver, and kidney function
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion Criteria
- Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
- Investigational drug within 30 days of the start of treatment
- Subjects with known brain metastasis
- Uncontrolled medical disorder such as infection or cardiovascular disease
- Subjects known to be HIV positive
- Pregnant or breastfeeding women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
The Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Cancer Therapy and Research Center
🇺🇸San Antonio, Texas, United States